GlassScriptPhysician profile
Mohammad Aiman Sheatt
NPI 1083708358
$388,985.13
in general payments reported to CMS, 2019-2025
58 companies · $112K in 2025
The $112K reported for 2025 was more than what 99% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $90K · 2020: $27K · 2021: $12K · 2022: $33K · 2023: $37K · 2024: $79K · 2025: $112K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $183K · Consulting Fee: $16K · Travel and Lodging: $16K · Food and Beverage: $12K · Education: $182.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $183,438.78 |
| Consulting Fee | $15,825.00 |
| Travel and Lodging | $15,805.93 |
| Food and Beverage | $12,134.66 |
| Education | $181.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $112,384.11 | 2019-2025 | Uptravi, Opsumit, Opsynvi |
| Mylan Specialty L.P. | $71,076.88 | 2019-2024 | Yupelri, Yupelri |
| Genzyme Corporation | $45,843.04 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $39,371.54 | 2019-2025 | Dupixent |
| Merck Sharp & Dohme LLC | $39,062.03 | 2019-2025 | Winrevair, Zerbaxa, Recarbrio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25,299.42 | 2019-2025 | Ofev, Stiolto Respimat, Jascayd |
| Glaxosmithkline, LLC. | $21,228.58 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Sunovion Pharmaceuticals INC. | $9,231.33 | 2019-2020 | |
| Viatris Specialty LLC | $7,639.38 | 2025 | Yupelri |
| Bayer Healthcare Pharmaceuticals INC. | $7,558.29 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $2,379.68 | 2019-2025 | Fasenra, Breztri, Tezspire |
| United Therapeutics Corporation | $1,662.79 | 2019-2025 | Tyvaso, Tyvaso, Orenitram |
| Grifols USA, LLC | $1,122.41 | 2019-2025 | Prolastin-C Liquid |
| Fisher & Paykel Healthcare Limited | $700.00 | 2025 | Fisher & Paykel Healthcare |
| Vertex Pharmaceuticals Incorporated | $466.67 | 2021 |
Show all 57 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $465.51 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $444.91 | 2020-2025 | Glassia |
| Insmed, INC. | $303.25 | 2021-2025 | Arikayce, Brinsupri |
| Genentech USA, INC. | $266.43 | 2019-2024 | Xolair, Esbriet |
| Amgen INC. | $222.59 | 2019-2025 | Tezspire |
| Eisai INC. | $220.20 | 2020-2021 | |
| Philips North America LLC | $184.28 | 2019-2022 | |
| Astellas Pharma US INC | $141.23 | 2019-2023 | Cresemba |
| Inogen, INC. | $121.67 | 2022-2023 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Paratek Pharmaceuticals, INC. | $118.31 | 2020-2025 | Nuzyra |
| Gilead Sciences, INC. | $103.07 | 2019-2021 | |
| Covis Pharma Gmbh | $100.02 | 2021-2022 | |
| Electromed, INC. | $95.64 | 2019-2025 | Smartvest |
| Verona Pharma, INC. | $92.27 | 2025 | Ohtuvayre |
| Fisher & Paykel Healthcare INC | $84.32 | 2019-2024 | Fisher & Paykel Healthcare |
| Harmony Biosciences LLC | $83.19 | 2021-2022 | |
| Axsome Therapeutics, INC. | $80.43 | 2023-2024 | Sunosi |
| Akcea Therapeutics, INC. | $71.88 | 2019 | |
| Novartis Pharmaceuticals Corporation | $69.97 | 2020-2023 | |
| Circassia INC. | $68.84 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $67.45 | 2020-2022 | |
| Mallinckrodt Hospital Products INC. | $62.17 | 2020-2021 | |
| Vanda Pharmaceuticals INC. | $60.42 | 2022-2023 | Hetlioz |
| Baxter Healthcare | $51.15 | 2022-2023 | Hillrom - Vest System Model 105 Home Care |
| Pfizer INC. | $46.16 | 2019-2025 | |
| Pulmonx Corporation | $34.44 | 2022-2024 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Chartis Catheter |
| Portola Pharmaceuticals, LLC | $32.19 | 2019 | |
| Csl Behring | $31.50 | 2019 | |
| Tactile Systems Technology INC | $25.49 | 2024 | Flexitouch Plus, Entre Plus |
| Janssen Pharmaceuticals, INC | $21.32 | 2020-2021 | |
| Allergan, INC. | $20.88 | 2020 | |
| 3b Medical, INC. | $19.24 | 2023 | Luna |
| Mayne Pharma Commercial LLC | $18.46 | 2020 | |
| Liquidia Technologies, INC. | $17.86 | 2025 | Yutrepia |
| La Jolla Pharmaceutical Company | $17.03 | 2025 | Giapreza |
| Idorsia Pharmaceuticals US INC | $16.86 | 2024 | Quviviq |
| Resmed Corp | $15.59 | 2021 | |
| Advanced Respiratory, INC | $15.56 | 2020 | |
| Shire North American Group INC | $13.40 | 2019 | |
| Aytu Biopharma, INC. | $11.50 | 2019 | |
| Arbor Pharmaceuticals, INC. | $11.32 | 2019 | |
| Bio Products Laboratory USA, INC. | $10.98 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammad Sheatt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.